ProCE Banner Activity

DESTINY-Gastric01: Trastuzumab Deruxtecan in Previously Treated, HER2+ Advanced Gastric or GEJ Adenocarcinoma

Slideset Download
Conference Coverage
In patients with advanced HER2+ gastric/GEJ cancer previously treated with trastuzumab, trastuzumab deruxtecan significantly improved response and OS vs standard chemotherapy.

Released: June 01, 2020

Expiration: May 31, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono